Pharmaceuticals News and Research

RSS

Kessler Foundation wins $735,000 grant for training rehabilitation researchers

Guang Yue, PhD, director of Human Performance and Engineering Research at Kessler Foundation, has been awarded a $735,000 grant from the National Institute on Disability, Independent Living, and Rehabilitation Research.

18 Jan 2018

Researchers identify new anti-inflammatory drug target

A new study suggests that parmodulins may provide anti-inflammatory and anti-thrombotic protection to endothelial cells, without interfering with clotting.

16 Jan 2018

The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health

A pioneering technology that allows patients to control their Parkinson’s disease symptoms using an iPod will be showcased at Arab Health by a renowned UK hospital.

16 Jan 2018

Research opens door to development of new treatment for type 2 diabetes

The team lead by Sílvia Vilares Conde, from CEDOC-NOVA Medical School, in collaboration with the pharmaceutical company Galvani Bioelectronics, demonstrated through findings in rats that is possible to restore insulin sensitivity and glucose homeostasis, by modulating electrically the carotid sinus nerve, the sensitive nerve that connects the carotid body with the brain. The study is published in Diabetologia, the journal of the European Association for the Study of Diabetes.

15 Jan 2018

FDA grants approval for first drug to treat inherited breast cancer

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast cancer that have spread (metastasized) and whose tumors have a specific inherited (germline) genetic mutation, making it the first drug in its class (PARP inhibitor) approved to treat breast cancer, and it is the first time any drug has been approved to treat certain patients with metastatic breast cancer who have a "BRCA" gene mutation.

15 Jan 2018

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LYNPARZA (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

12 Jan 2018

Genetic analysis can enhance outcomes of depression treatment

The failure of drugs such as SSRIs, used to treat depression, can be a result of genetic variations in patients.

12 Jan 2018

New drug candidates may offer breakthrough in treatment of COPD

The study was a cooperative effort between the team headed by assistant professor Dr Jürgen Knobloch from the Medical Clinic III for Pneumology, Sleep and Respiratory Medicine at the Bergmannsheil University Hospital in Bochum, Germany, and Prof Dr Andrea Koch, member of the German Center for Lung Research, previously in Bochum, now at the Medical Clinic V for Pneumology at the LMU University Hospital in Munich, as well as a team from the company RespiVert Ltd, a subsidiary of Janssen Biotech Inc., and Prof Dr Erich Stoelben from the Lung Clinic in Köln-Merheim.

12 Jan 2018

Insilico Medicine develops new deep-learning based hematological human aging clock

Today, Insilico Medicine, Inc., a Baltimore-based company specializing in the application of artificial intelligence for drug discovery, biomarker development and aging research, announced a publication of a research paper titled "Population-specific biomarkers of human aging: a big data study using South Korean, Canadian and Eastern-European patient populations" in The Journal of Gerontology.

11 Jan 2018

Novel partnership creates Europe's first antimicrobial nitrile gloves

Unigloves new Fortified single use gloves incorporate silver ion technology from BioCote, which has been scientifically proven to destroy 90% of harmful bacteria within just 15 minutes and 99.5% in only two hours.

11 Jan 2018

Pfizer to stop Alzheimer’s and Parkinson’s disease research

Pharmaceutical giant Pfizer has announced its intention to stop research and development in areas including Alzheimer’s disease and Parkinson’s disease.

11 Jan 2018

Alzheimer’s Research UK calls on pharma to continue supporting dementia research

Alzheimer’s Research UK is calling for a recommitment from pharmaceutical companies to continue efforts to fund research into dementia, the leading cause of death in the UK.

10 Jan 2018

HHS nominee vows to tackle high drug costs, despite his ties to industry

Senate Democrats on Tuesday pressed President Donald Trump's nominee for the top health post to explain how he would fight skyrocketing drug prices — demanding to know why they should trust him to lower costs since he did not do so while running a major pharmaceutical company.

9 Jan 2018

Vanderbilt and Lundbeck collaborate to develop novel approach for treating schizophrenia

Vanderbilt University has signed separate licensing and research collaboration agreements with Lundbeck, a global pharmaceutical company based in Denmark, to develop a novel approach for treating schizophrenia.

9 Jan 2018

Pharmaceutical pollution can make aquatic microbial communities resistant to drugs

In urban streams, persistent pharmaceutical pollution can cause aquatic microbial communities to become resistant to drugs. So reports a new study published today in the journal Ecosphere.

9 Jan 2018

Regeneron forms consortium to accelerate largest widely-available human sequencing resource

By the end of 2019, Regeneron plans to sequence the exomes of all 500,000 people within the UK Biobank resource, all with associated health records, creating an unprecedented resource linking human genetic variations to human biology and disease.

9 Jan 2018

Exercise training may help middle-aged people to reduce heart failure risk from sedentary lifestyle

Middle-aged couch potatoes may reduce or reverse the risk of heart failure associated with years of sitting if they participate in two years of regular aerobic exercise training, according to a new study in the American Heart Association's journal Circulation.

8 Jan 2018

Polygenic risk score predicts early-onset heart disease risk

A risk score based on multiple genetic differences, or polygenic risk score, predicted significantly more cases of early-onset heart disease than standard tests for single genetic defects, according to new research in the American Heart Association's journal Circulation: Genomic and Precision Medicine.

8 Jan 2018

Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS

Sangamo Therapeutics, Inc. and Pfizer Inc. today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

8 Jan 2018

Supercharged old drugs could destroy world's most dangerous superbugs

An old drug supercharged by University of Queensland researchers has emerged as a new antibiotic that could destroy some of the world's most dangerous superbugs.

5 Jan 2018

Pharmaceuticals News and Research

Kessler Foundation wins $735,000 grant for training rehabilitation researchers

Researchers identify new anti-inflammatory drug target

The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health

Research opens door to development of new treatment for type 2 diabetes

FDA grants approval for first drug to treat inherited breast cancer

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

Genetic analysis can enhance outcomes of depression treatment

New drug candidates may offer breakthrough in treatment of COPD

Insilico Medicine develops new deep-learning based hematological human aging clock

Novel partnership creates Europe's first antimicrobial nitrile gloves

Pfizer to stop Alzheimer’s and Parkinson’s disease research

Alzheimer’s Research UK calls on pharma to continue supporting dementia research

HHS nominee vows to tackle high drug costs, despite his ties to industry

Vanderbilt and Lundbeck collaborate to develop novel approach for treating schizophrenia

Pharmaceutical pollution can make aquatic microbial communities resistant to drugs

Regeneron forms consortium to accelerate largest widely-available human sequencing resource

Exercise training may help middle-aged people to reduce heart failure risk from sedentary lifestyle

Polygenic risk score predicts early-onset heart disease risk

Sangamo and Pfizer partner for development of new zinc finger protein gene therapy to treat ALS

Supercharged old drugs could destroy world's most dangerous superbugs

Free eBook - From lab to market: Accelerate your bioprocessing journey eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring